Breast Cancer

Breast cancer subtyping (Luminal, HER2+, triple-negative, etc.) shapes endocrine, anti-HER2, and chemo/IO strategies. Recurrent nodes include ER/PR, ERBB2, Ki-67, BRCA1/2, PIK3CA/PTEN, and CDK4/6. We provide subtype biomarker antibodies and probes (CDK4/6, PARP, PI3Kα, mTOR) for resistance clones, signaling feedback, and combination studies.

Focus areas: CDK4/6–endocrine resistance, HER2-low & ADCs, TNBC immune milieu, BRCA/HRD & PARP

Breast cancer–related antibodies (curated)

Loading…

Hot topics & directions

  • CDK4/6 inhibitor resistance: Rb loss, Cyclin E1 upregulation, replication stress reshaping retreatment.
  • HER2 & ADCs: HER2-low boundaries & bystander killing across heterogeneity.
  • TNBC immunotherapy: TILs, PD-L1, chemo-induced ICD coupling.
  • PI3K/AKT axis: PIK3CA/PTEN lesions feeding endocrine/targeted feedback loops.

Related targets

Hormone receptors
ESR1, PGR, AR (contextual)
Growth & HER2
ERBB2 (HER2), ERBB3, ERBB4
Proliferation / DDR
MKI67 (Ki-67), BRCA1, BRCA2, PALB2, PARP1
PI3K / cell cycle
PIK3CA, PTEN, AKT1/2/3, CDK4, CDK6, CCND1

Key signaling pathways

  1. ER–coactivator → transcriptional programs
    Programs Luminal proliferation and endocrine response.
  2. ERBB2–PI3K–MAPK crosstalk
    HER2 amplification drives survival and resistant clone selection.
  3. CDK4/6–RB–E2F
    G1/S checkpoint hub for endocrine combinations.
  4. PI3K–AKT–mTOR
    Metabolism, protein synthesis, and immunosuppressive niches intersect.

Tool compounds (research use)

Commonly used for mechanistic studies; follow your lab SOP, compound datasheets, and ethics approvals.

CompoundTargets / pathwaysExperimental notes
PalbociclibCDK4/6HR+/HER2- endocrine combos; mind Rb loss conferring primary resistance.
RibociclibCDK4/6Cycle arrest readouts with endocrine/targeted partners; pair p-RB / Cyclin E1.
OlaparibPARP1/2Synthetic lethality in gBRCA/HRD; watch stacked DDR toxicities.
AlpelisibPI3Kα (PIK3CA-mutant)PIK3CA-mutant subsets with endocrine partners; monitor hyperglycemia/rash.
TamoxifenER (SERM; context-dependent agonism)Classic endocrine tool; tissue/dose determines agonist vs antagonist phenotypes.
FulvestrantER (degrader)ER downregulation/resistance models; translate depot PK in animals carefully.
EverolimusmTORC1Post-endocrine PI3K/AKT/mTOR axis probe; mind immunosuppression/metabolic AE.